Sunshine Biopharma Inc. filed a Definitive Proxy Statement on November 12, 2026, seeking shareholder votes on director elections, auditor ratification, and an expansion of its 2023 Equity Incentive Plan ahead of a virtual annual meeting scheduled for December 29, 2026.

Key Highlights

  • Annual meeting date: December 29, 2026, at 10:00 a.m. Eastern Time, held entirely online via webcast.
  • Record date: November 4, 2026, with 823,772 shares of common stock and 130,000 shares of Series B Preferred Stock outstanding as of that date.
  • Voting power: Each share of Series B Preferred Stock, all of which are held by the chief executive officer according to the filing, carries 1,000 votes per share.
  • Board election: Shareholders are asked to elect five directors to serve until the 2027 Annual Meeting or until successors are duly elected and qualified.
  • Auditor ratification: The filing proposes ratifying M&K CPAS, PLLC as independent registered public accountant for the year ending December 31, 2026.
  • Equity plan amendment: Shareholders are asked to approve an increase in shares authorized under the 2023 Equity Incentive Plan to 7,000,000.
  • Filing company: Sunshine Biopharma Inc. (NASDAQ:SBFM), a Colorado corporation headquartered at 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301.

Sunshine Biopharma Puts Equity Plan Expansion and Board Composition to Shareholder Vote

According to the filing, Sunshine Biopharma Inc. is a Colorado corporation that has set December 29, 2026 as the date for its 2026 Annual Meeting of Shareholders, to be conducted exclusively as a virtual webcast. The proxy statement was dated and filed November 12, 2026, with Dr. Steve N. Slilaty identified as Chairperson of the Board of Directors and signatory of the shareholder letter accompanying the materials.

The filing discloses that as of the November 4, 2026 record date, there were 823,772 shares of common stock outstanding alongside 130,000 shares of Series B Preferred Stock. The proxy statement notes that all Series B Preferred Stock shares are held by the company's chief executive officer, and each such share carries 1,000 votes, a structure that concentrates significant voting power. Holders of common stock and Series B Preferred Stock of record at the close of business on the record date are entitled to vote at the meeting.

Among the four items presented for shareholder action, the proposal to amend the 2023 Equity Incentive Plan is notable in its specificity: the filing identifies the requested new authorization ceiling as 7,000,000 shares of common stock. The company also seeks ratification of M&K CPAS, PLLC as its independent registered public accountant for the fiscal year ending December 31, 2026. Shareholders who hold shares through a broker or bank are directed to register in advance and use a 16-digit control number included on their proxy card to participate and vote online.

What Was Disclosed

Sunshine Biopharma Inc. filed a Definitive Proxy Statement covering its 2026 annual shareholder meeting. The filing details four voting proposals: election of five directors, auditor ratification, an equity plan share increase to 7,000,000, and any other properly raised business. The record date was November 4, 2026.